Top specialty therapy drugs by PMPY spending U.S. 2016

Top 10 specialty therapy drugs in the U.S. by per-member-per-year (PMPY) spending in 2016 (in U.S. dollars)*

Leading specialty therapy drugs in the U.S. by PMPY spending 2016

Last update:

Feb 13, 2017

Author:

��ƽ�� Research Department

Region:

United States

Survey time period:

From 01/01/2016 to 31/12/2016

This statistic shows the leading specialty therapeutic drugs in the United States in 2016, based on per-member-per-year spending. Humira Pen (adalimumab) for inflammatory conditions had the highest PMPY spending, reaching over 45 U.S. dollars in that year.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Top 10 specialty therapy drugs in the U.S. by per-member-per-year (PMPY) spending in 2016 (in U.S. dollars)*

Get in touch with us for additional information

��ƽ��